Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.

Company Overview and News

KLCI holds position above 1,800 level, gains seen capped

2018-08-09 theedgemarkets
KUALA LUMPUR (Aug 9): The FBM KLCI managed to hold its position above the 1,800-point level at mid-morning today, but gains were seen capped in line with the subdued regional markets.
HLFBF 7172 5198 1082 7412 7043 7077 2852 5029 5347 5225 1201 3301 TNABY 5819 2836 TNABF Q0F IHHHF 3719

Bursa rebounds to open higher

2018-08-07 malaymail
KUALA LUMPUR, Aug 7 — Bursa Malaysia rebounded from yesterday's losses to open higher today, taking cue from the overnight performance of Wall Street and amid rising crude oil prices.
0143 7172 PNADF PBLOF 1295 BSMAF PNAGF 6033 1818

KLCI rises 0.29% as select blue chips lift

2018-08-07 theedgemarkets - 1
KUALA LUMPUR (Aug 7): The FBM KLCI rose 0.29% in early trade this morning, tracking the steady regional markets, lifted by select index-linked blue chips.
HLFBF 7172 1082 BATS 4162 5246 3034 6033 KLKBY 2445 PNADF 5819 PNAGF 3719

KLCI claws into positive territory as Tenaga lifts

2018-08-03 theedgemarkets
KUALA LUMPUR (Aug 3): The FBM KLCI clawed into positive territory at the midday break today, lifted by gains at Tenaga Nasional Bhd and other select blue chips.
HLFBF 7172 2089 5014 0020 2852 KLKBY 5347 3867 TNABY MYTEF PNAGF UPBMF 1082 7765 6033 5139 2445 PNADF 4863 6645 0900 5819 MYPRY TNABF

KLCI pares loss as foreign selling slows down

2018-07-23 theedgemarkets
KUALA LUMPUR (July 23): The FBM KLCI pared some of its losses at midday break today, despite weaker regional markets, as foreign selling of local equities remained measured for the fourth week running.
HLFBF 7172 UPBMF 1082 BATS 4162 7006 2089 7055 LIIHF KLKBY 5238 2445 4588 3867 5738 0026

KLCI dips 0.24% in line with regional markets

2018-07-23 theedgemarkets
KUALA LUMPUR (July 23): The FBM KLCI dipped 0.24% at mid-morning today, tracking regional losses, weighed by select index-linked blue chips.
7172 UPBMF 7006 2089 5014 9334 6033 5101 LIIHF 7123 KLKBY 5238 2445 4588 PNADF 5738 7216 0026 MYPRY 2836 PNAGF

Bursa snaps nine-day winning streak to end lower

2018-07-20 malaymail
KUALA LUMPUR, July 20 — Bursa Malaysia snapped a nine-day winning streak to close easier today on technical correction, amid a recovery in the Chinese market and overnight Wall Street decline, said a dealer.
7172 PBLOF 1589 1295 BSMAF 1818

Bursa Malaysia closes higher for eighth straight day

2018-07-18 malaymail
KUALA LUMPUR, July 18 — Bursa Malaysia closed higher for the eighth straight day today with gains seen across-the-board, save for the mining counter, as the Federal Reserve (Fed) Chair’s testimony last night had a positive spillover throughout markets, said a dealer.
0143 7172 PBLOF 1295 BSMAF 1818

KLCI reverses loss, rises 0.31% in line with region

2018-07-18 theedgemarkets
KUALA LUMPUR (July 18): The FBM KLCI reversed its earlier losses and rose 0.31% at midday break, tracking gains at most Asian markets.
HLFBF 7172 PBLOF 7053 1082 7087 1295 9334 7123 0143 4863 0156 8613 0026 6888 5819 AXXTF MYTEF 2836

KLCI pares down loss, tracks advance at key Asian markets

2018-07-18 theedgemarkets
KUALA LUMPUR (July 18): The FBM KLCI pared down its earlier losses substantially at mid-morning today, tracking the advance at key Asian markets.
7172 PBLOF 7053 8133 7087 1295 7153 7123 7079 0176 4588 3026 6645 5819

KLCI rises 1.38% on 1H18 window dressing, led by Tenaga

2018-06-29 theedgemarkets
KUALA LUMPUR (June 29): The FBM KLCI rose 1.38% at mid-morning today on 1H18 window-dressing activities, led by gains in Tenaga Nasional Bhd.
7172 7251 SPMXF 8621 7113 TPGVF 7765 5168 1481 5255 TGLVY 5139 KLKBY 2445 5216 SPMXY 5347 3026 0900 TNABY TNABF 1929 HRGHY

KLCI pares losses on feeble window-dressing activity

2018-06-28 theedgemarkets
KUALA LUMPUR (June 28): The FBM KLCI pared some of its losses at the midday break today amid some feeble window-dressing activities ahead of the final trading day of the first half of 2018 tomorrow.
HLFBF 7172 7052 PBLOF 7251 MLYNF 7113 BATS TPGVF 4162 1295 2089 9334 5347 3867 TNABY 2836 PNAGF MLYBY UPBMF 1082 2291 6033 TGLVY 1155 PNADF TNABF 3719

Related Articles

REPH: Recro Pharma Analysis and Research Report

10h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

11h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

11h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="